P&G board members Lee, Snyderman retire
CINCINNATI Procter & Gamble has announced the retirement of Charles Lee and Ralph Snyderman from its board of directors.
Lee has been a director since 1994 and Snyderman has been a director since 1995. They both recently celebrated their 70th birthday.
Current director, Patricia Woertz, has been designated chair of P&G’s audit committee while the chair of P&G’s innovation and technology committee will be taken by current director, Scott Cook.
“Chuck and Ralph have served P&G’s board with distinction for more than 15 years. Their insights, counsel and leadership have been invaluable,” stated Bob McDonald, P&G’s chairman of the board, president and CEO. “We will miss them both but wish them continued success.”
Sparking clinical skin care
LOS ANGELES —Following years of research and 10 new technology patents, skin care brand Neutrogena has introduced its new Neutrogena Clinical.
To develop Neutrogena Clinical, scientists at the company looked to bioelectricity, the body’s innate electrical signaling system. Neutrogena scientists discovered a way to create tiny, ion-mineral conductors within a topical formulation that, once activated, work like “miniaturized batteries” to simulate bioelectricity and increase positive ion flow. This helps minimize visible signs of collagen loss, improve facial definition and reduce the appearance of wrinkles and sagging skin.
The collection, which hit stores the first week of March, includes facial lifting wrinkle treatment SPF 30 ($39.99); eye lift contouring treatment ($39.99); lifting wrinkle treatment starter system—SPF 30 and eye ($49.99); and facial lifting wrinkle treatment night ($39.99).
Break away from outbreaks
BARRINGTON, Ill. —Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment March 1. The only over-the-counter treatment for genital herpes, Fast-Results! answers an unmet need of people who suffer painful symptoms associated with genital herpes outbreaks, and it can be used in conjunction with a prescription therapy for genital herpes.
Fast-Results! genital herpes treatment is comprised of Merix’s patented technology Viracea, which contains an approved ingredient under the Food and Drug Administration OTC antiseptic/antimicrobial monograph, the company stated.
According to the Centers for Disease Control and Prevention, 16% of Americans currently suffer from genital herpes.
No matter how the herpes treatment is categorized, it should drive traffic. According to Nielsen Group data for the 52 weeks ended Feb. 20 across food, drug and mass, all lip remedies were relatively flat, up only 0.7% to $530.7 million. Foot preparations, which include jock itch remedies and other antifungals, totaled $193.6 million in sales, down 7.4%.